City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
City Therapeutics closed its upsized IPO of 12,777,777 shares at $18.00 per share, including 1,666,666 shares from the underwriters' fully exercised option. Aggregate gross proceeds were approximately $230.0 million before underwriting discounts and expenses, with all shares offered by the company. The clinical-stage RNAi biotech began trading on Nasdaq under ticker CTY on October 16, 2026; Goldman Sachs, Jefferies, Stifel and Oppenheimer acted as joint book-runners.
Key figures
- Deal Value Usd
- 230000000
- Offering Price
- 18
- Shares Offered
- 12777777
- Gross proceeds
- $230.0 million
- Ipo trading start
- 2026-10-16
- Option shares exercised
- 1666666
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.